Objective:

To document the laboratory kinetics of urinary aluminum levels following pulsed 660 nm photobiomodulation (PBM) in a child with autism spectrum disorder (ASD).

Approach:

Key Findings:

• Baseline urinary aluminum levels were stable at 10.0 and 9.8 µg/g creatinine.
• After PBM, urinary aluminum levels increased to 58 µg/g on Day 3 and peaked at 98 µg/g on Day 7.
• At two-month follow-up, urinary aluminum remained elevated at 49 µg/g.
• Mercury levels exceeded reference values in all specimens, with a follow-up level of 8.4 µg/g creatinine.

Interpretation:

The observed increase in urinary aluminum excretion following PBM does not provide sufficient evidence for systemic mobilization or clinical benefit.

Limitations:

• The study is a single case report without controlled comparisons.
• No mechanistic biomarkers were evaluated to support claims of enhanced metal clearance.

Conclusion:

The findings are hypothesis-generating and indicate the need for controlled studies with verified dosimetry and validated outcomes.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.